ABSTRACT
Objective To explore the clinical effect of dopamine,phentolamine,recombinant interferon α combined with nasal continuous positive airway pressure(CPAP) ventilation in treating severe infantile bronchiolitis.Methods Ninety-five cases of infantile severe bronchiolitis were divided into the observation group(55 cases) and control group (40 cases).The control group was given the combined treatment scheme of dopamine,phentolamine and recombinant interferon α,while on this basis the observation group was added with NCPAP.The curative effects were compared between the two groups.Results The total effective rate in the observation group was significantly higher than that in the control group(P0.05);the recurrence rate and death rate in the observation group were significantly lower than those in the control group with statistical difference(P0.05).Conclusion Dopamine,phentolamine,recombinant interferon α combined with NCPAP has obviously clinical effect for treating infantile severe bronchiolitis,can effectively improve the blood gas analytical indexes,reduces the signs and symptoms relief time,reduces the rates of relapse and death,and has higher clinical application value.
ABSTRACT
This study aimed to evaluate the efficacy of Sophora flavescens gel in treatment of cervical HPV infection. 120 patients with cervical HPV infections were selected from department of gynecology, the first affiliated hospital, Heilongjiang university of Chinese medicine. They were randomly divided into three groups: test group(S. flavescens gel, 40 cases), control group(human recombinant interferon α-2b gel, 40 cases) and combined application group(combination of the above two, 40 cases). The treatment course was three months in all three groups. Before and after treatment, the changes of HPV viral load and the changes of viral load for different HPV types were observed.The results could provide guidance for clinical application of S. flavescens gel.
ABSTRACT
Objective:To investigate the clinical efficacy of recombinant human interferon α-2b gels combined with ulcer powders for external use in the treatment of cervicitis patients with human papillomavirus infection. Methods: Totally 76 cases of cervicitis patients with human papillomavirus infection were randomly divided into the observation group and the control group. The observation group was treated by recombinant human interferonα-2b gels combined with ulcer powders for external use through vaginal administration, once every 2d on bedtime. The control group was treated only by ulcer powders for external use. After the 6-month treatment, the HPV negative conversion rate, clinical efficacy and adverse drug reactions in the two groups were detected. Results:After the treatment, the HPV negative conversion rate of the observation group was 83. 33%, which was higher than that of the control group (60. 00%, P <0. 001). The total effective rate of the observation group was 88. 89%, which was higher than that of the control group (82. 50%, P < 0. 05). Conclusion: The clinical efficacy of recombinant human interferon α-2b gels combined with ulcer powders for external use in the treatment of cervicitis patients with human papillomavirus infection is significant, which is worthy of wider application.
ABSTRACT
Objective To investigate the effect of recombinant interferon in the treatment of chronic hepatitis and the influence of neutralizing antibody (NA) on its clinical efficacy.Methods 80 cases with chronic hepatitis were randomly divided into the treatment group(n=40) and control group(n=40).The content of HBV DNA was determined by fluorescence quantitative polymerase chain reaction ( PCR) assay.The neutralizing antibodies against interferon were measured by antiviral-neutralizing assay(AVA).Results After the treatment,the content of HBV DNA in the observation group was significantly lower than before treatment (F=12.55,P0.05).The contents of HBV DNA in NA positive group had no significant difference before and after treatment (F=0.88,P>0.05);The contents of HBV DNA in NA negative group had significant difference before and after the treatment ( F=11.55,P<0.05).In 80 cases,degree of cell lesions in 0 grade(10 cases),1 grade(25 cases),2 grade (25 cases),3 grade (12 cases) and 4 grade(8 cases).Conclusion The recombinant interferon in the treatment of chronic hepatitis has certain effect,but NA can affect its treatment effect .
ABSTRACT
La leucemia mieloide crónica del adulto es la hemopatía maligna más frecuente dentro de los síndromes mieloproliferativos. En un estudio retrospectivo longitudinal realizado entre enero de 1985 y diciembre de 2009, se evaluaron 46 pacientes en fase crónica atendidos en el Instituto de Hematología e Inmunología. Todos recibieron tratamiento inicial citorreductor y posteriormente interferón ? recombinante (INF?r) + citosina arabinósido. El 41,0 por ciento de los enfermos presentó un índice pronóstico de Sokal de alto riesgo. Las manifestaciones clínicas más frecuentes al diagnóstico fueron astenia (37 por ciento), esplenomegalia (31 por ciento) y pérdida de peso (28,3 por ciento). La respuesta hematológica parcial y completa fue del 26,8 por ciento y 65,9 por ciento a los 6 meses; la respuesta citogenética y molecular completa de 9,1 por ciento y 16,3 por ciento, respectivamente. Las reacciones adversas más frecuentes fueron fiebre (34,9 por ciento), trombocitopenia (26,2 por ciento) y síndrome general (23,8 por ciento). El 47,8 por ciento de los casos mostraron resistencia o intolerancia al INF?r y el 90,9 por ciento falleció por progresión de la enfermedad. La sobrevida global a los 5 años fue del 63,8 por ciento y la sobrevida libre de eventos a los 3 años fue del 68,9 por ciento. Según el índice pronóstico de Sokal, la sobrevida global mostró diferencia significativa entre los 3 grupos (p= 0,005), no así para la sobrevida libre de eventos (p= 0,165). El tratamiento con INF?r mostró resultados superiores a los de algunos países desarrollados y constituye una opción terapéutica eficaz en Cuba
Chronic myeloid leukemia is the most frequent myeloproliferative syndrome in adults. In a longitudinal retrospective study performed between January 1985 - December 2009, 46 patients in chronic phase diagnosed at the Institute of Hematology and Immunology were evaluated. They received cytoreductor agent as first treatment followed by interferon ?2 + cytosar. Forty one percent showed high risk Sokal prognosis score. The most frequent clinical manifestations at diagnosis were asthenia (37 percent), splenomegaly (31 percent) and weigh lost (28.3 percent). The partial and complete hematological response was of 26,8 percent and 65.9 percent after 6 months and the complete cytogenetic and molecular response was of 9.1 percent and 16.3 percent. The most frequent adverse reactions were: fever (34.9 percent), thrombocytopenia (26.3 percent) and general syndrome (23.8 percent). Resistance or intolerance to INF?2 was found in 47.8 percent of the patients and 90.0 percent died due to progression of the disease. The 5 year overall survival was of 63.8 percent and the 3 years free event survival was of 68.9 percent. According to Sokal prognosis score the overall survival showed significant difference between groups (p= 0.005) but there was no significant difference for free event survival (p= 0.165). The INF?2 treatment in our patients showed better results than those obtained in different developed countries and is an effective therapeutic option in Cuba
Subject(s)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/epidemiology , InterferonsABSTRACT
BACKGOUND: Interferon-alpha2b has already proven to be effective in the clinical treatment of virus-originated diseases such as hairy cell leukemia, condyloma acuminatum, and AIDS-related Kaposi's sarcoma. The use of recombinant interferon-alpha2b may allow various types of wart to be treated relatively atraumatically and with less incidence of recurrence. OBJECTIVE: We tried to compare the effectiveness and safety of intralesional injections of recombinant interferon-alpha2b with natural interferon-alpha2b in the treatment of patients with various types of wart. METHOD: Patients with more than two warts were treated by injecting the different warts with 0.5 to 1.0X105 IU/1mm3 of recombinant and natural interferon-alpha2b, twice per week for 4 to 20 weeks. The response to treatment was followed up at 36 weeks. RESULTS: At the end of treatment, clearing of the treated warts had occurred in 83.3% of the recombinant interferon-alpha2b group and 91.6% of the natural interferon-alpha2b group. A more rapid cure rate was observed in the natural interferon-alpha2b group than in the recombinant interferon-alpha2b group. The rest showed partial improvement. With evaluation for relapse up to 16 weeks after treatment, warts were found to relapse in 11.1% of both the recombinant and natural interferon groups. CONCLUSION: Intralesional natural interferon-alpha2b has a better therapeutic effect than recombinant interferon-alpha2b, and may be considered as a therapeutic modality of recalcitrant verruca or when it can be anticipated that destructive techniques or blistering agents will not be tolerated.
Subject(s)
Humans , Blister , Incidence , Injections, Intralesional , Interferons , Leukemia, Hairy Cell , Recurrence , Sarcoma, Kaposi , WartsABSTRACT
OBJECTIVE:To prepare recombinant interferon(INF)?1b chitosan plastics and to establish a way for its quality control.METHODS:The plastics was prepared with chitosan as the main excipients,the content of INF?1b was de-termined by di-quinoline methanoic acid kit,the stability of the plastics was determined and its skin irritation test was con-ducted.RESULTS:The linear range for recombinant INF?1b in the prepared paint was1～11mg/L(r=0.9999)with methodological recovery rate at101.04%,RSD=1.05%(n=5).CONCLUSION:The recombinant INF?1b chitosan plastics is simple in preparation,accurate in assaying,stable in quality yet the skin irritation induced by which was failed to be noted.
ABSTRACT
This study was performed to investigate the clinical efficacy of intralesional recombinant interferon-γ (IFN-γ) in the treatments of warts, using a placebo comparison. Warts of each groups were injected with INF-γ containing 5×10⁶ IU/ml (high dose), 1×10⁶ IU/ml (low dose), or distilled water for injection as placebo, respectively, twice weekly for three weeks. The final therapeutic efficacy was determined on the fourth week after the beginning of therapy. Among the 74 patients with periungual warts, plantar warts, or warts of other sites, complete clearing of the treated warts at week four occurred in 56% of the 36 patients receiving the high dose IFN-γ compared to 30% of the 53 receiving the low dose IFN-γ and 17% of the 36 receiving the placebo. Marked improvement showing 75% or greater regression of wart lesions was noted as 89% of patients receiving the high dose INE compared with 55% receiving the low dose IFN and 50% receiving the placebo. The group of patients with warts of other sites showed the best response. The group receiving the high dose IFN experienced some adverse effects more frequently or more severely than the group receiving low dose IFN. However, the effects were relatively tolerable to the patients. Therefore, intralesional injection of the high dose IFN-γ may be more useful in treating warts than a low dose IFN-γ.
Subject(s)
Humans , Injections, Intralesional , Interferon-gamma , Treatment Outcome , Warts , WaterABSTRACT
A study evaluating the therapeutic effect of recombinant interferon-a ointment on several viral skin diseases was done. A total of 204 patients, 92 of herpes simplex, 90 of herpes zoster and 22 of varicella, were included in this study. Two different concentration of recombinant interferon-a ointment(l*10IU/g; group A, 1*10IU/g; group B) and placebo vehicle(control group) were applied topically on the early lesion of the disease. The evaluation of therapeutic effect was done by the measurement of time interval from the day of vesicle formation to the day of crust formation, The results were as follows; 1. Herpes sirnplex: Crust formation observed within 6 days in 70. 1% of group A. 63.9% of group B and 26.7%, of control group. The time of crust formation of group A and B was shorter than that of control group (p<0.01, P<0.05). 2. Herpes zoster: Crust formation observed within 10 days in 64. 3% of group A. 46.7% of group B and 33. 3% of control group. The time of crust formation of group A was shorter than that of control group (p<0.05). 3. Varicella: Crust formation observed within 6 days in 87. 5% of group A, 72.7% of group B and 66.7% of control group. Therefore we have been impressed that recombinant interferon-a ointment is an effective topical therapeutic agent and 1*10IU/g recombinant interferon-a clintment is more effective than 1*10IU/g recombioant interferon-a ointment for above viral skin diseases.